Pharming GroupPHAR +0.53%79 Gross Margin % is 90.83% as of Mar. 2026, which is 3% above its 10-year median of 88.00. GuruFocus rates PHAR with a GF Score™ of 79/100 and a GF Value™ of $14.28 (Fairly Valued). The stock has 1 warning sign investors should review. Among 737 Biotechnology companies, Pharming Group ranks better than 81.28% on this metric.
The historical rank and industry rank for Pharming Group's Gross Margin % or its related term are showing as below:
PHAR'
s Gross Margin % Range Over the Past 10 Years
Min: 70.5 Med: 88 Max: 91.46
Current: 88.16
During the past 13 years, the highestGross Margin % of Pharming Group was 91.46%. The lowest was 70.50%. And the median was 88.00%.
PHAR's Gross Margin % is ranked better than 81.28% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs PHAR: 88.16
Pharming Group had a gross margin of 90.83% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Pharming Group was -0.30% per year.
Pharming Group (NAS:PHAR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pharming Group had a gross margin of 90.83% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pharming Group Gross Margin % Related Terms
Pharming Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pharming Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAR vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Pharming Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pharming Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pharming Group (PHAR) has a Gross Margin % of 90.83% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharming Group and its competitors. This is near median its historical median of 88.00. Over the past decade, Pharming Group's Gross Margin % has ranged from 70.50 to 91.46. According to the industry distribution chart, Pharming Group ranks #138 out of 737 companies in the Biotechnology industry, placing it in the top 18.7%.
Is Pharming Group's Gross Margin % too high?
Pharming Group's current Gross Margin % of 90.83% is near median its 10-year median of 88.00. Over the past 10 years, this metric has ranged from a low of 70.50 to a high of 91.46. The Biotechnology industry median Gross Margin % is 60.92. Pharming Group's value of 90.83% is 49.1% above this industry median. Based on the distribution chart, Pharming Group ranks #138 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #138 out of 737 companies for Gross Margin %. This places Pharming Group in the top 19% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Pharming Group's value of 90.83% is 49.1% above this benchmark. Historically, Pharming Group's own Gross Margin % has ranged from 70.50 to 91.46 over the past decade. While the company's 10-year median is 88.00 vs. the industry median of 60.92, Pharming Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current Gross Margin % of 90.83% is 49.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Gross Margin % is 90.83%, which is near median its own 10-year median of 88.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.28, compared to a current price of $13.34 — trading 6.6% below its estimated fair value. The current Gross Margin % is 90.83%, which is near median its 10-year median of 88.00 and 49.1% above the Biotechnology industry median of 60.92. Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pharming Group (PHAR), the current Gross Margin % is 90.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.34 is trading 6.6% below its estimated GF Value™ of $14.28.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Gross Margin %: 90.83% (near median its 10-year median of 88.00)
GF Value™: $14.28 vs. price of $13.34 (6.6% below fair value)
Industry Position: 49.1% above the Biotechnology median (#138 of 737)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score
Get the complete analysis for PHAR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
